AU2015301338C1 - Antagonistic anti-OX40L antibodies and methods of their use - Google Patents

Antagonistic anti-OX40L antibodies and methods of their use Download PDF

Info

Publication number
AU2015301338C1
AU2015301338C1 AU2015301338A AU2015301338A AU2015301338C1 AU 2015301338 C1 AU2015301338 C1 AU 2015301338C1 AU 2015301338 A AU2015301338 A AU 2015301338A AU 2015301338 A AU2015301338 A AU 2015301338A AU 2015301338 C1 AU2015301338 C1 AU 2015301338C1
Authority
AU
Australia
Prior art keywords
seq
antibody
ox40l
ser
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301338A
Other languages
English (en)
Other versions
AU2015301338B2 (en
AU2015301338A1 (en
Inventor
Patrick Blanco
Haruyuki FUJITA
Shino Hanabuchi
HyeMee JOO
Yong-Jun Liu
Sangkon Oh
Hide Ueno
Sandra Zurawski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of AU2015301338A1 publication Critical patent/AU2015301338A1/en
Publication of AU2015301338B2 publication Critical patent/AU2015301338B2/en
Application granted granted Critical
Publication of AU2015301338C1 publication Critical patent/AU2015301338C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
AU2015301338A 2014-08-04 2015-08-03 Antagonistic anti-OX40L antibodies and methods of their use Active AU2015301338C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462032959P 2014-08-04 2014-08-04
US62/032,959 2014-08-04
PCT/US2015/043408 WO2016022468A1 (en) 2014-08-04 2015-08-03 Antagonistic anti-ox40l antibodies and methods of their use

Publications (3)

Publication Number Publication Date
AU2015301338A1 AU2015301338A1 (en) 2017-02-23
AU2015301338B2 AU2015301338B2 (en) 2021-03-25
AU2015301338C1 true AU2015301338C1 (en) 2021-07-22

Family

ID=55264394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015301338A Active AU2015301338C1 (en) 2014-08-04 2015-08-03 Antagonistic anti-OX40L antibodies and methods of their use

Country Status (7)

Country Link
US (2) US10167339B2 (enExample)
EP (1) EP3194445A4 (enExample)
JP (1) JP6628787B2 (enExample)
CN (1) CN107074951B (enExample)
AU (1) AU2015301338C1 (enExample)
IL (1) IL250428B (enExample)
WO (1) WO2016022468A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US20220372153A1 (en) * 2015-03-03 2022-11-24 Kymab Limited Synergistic combinations of ox40l antibodies for the treatment of gvhd
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018170764A1 (zh) * 2017-03-22 2018-09-27 深圳市博奥康生物科技有限公司 一种用于 RNAi 的载体及其应用
PT3697810T (pt) * 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
CN108458964A (zh) * 2017-10-31 2018-08-28 天津协和华美医学诊断技术有限公司 一种抗体组合物及其在淋巴浆细胞性淋巴瘤微小残留检测中的应用
EP3938389A4 (en) * 2019-03-12 2022-11-09 University Health Network TSG-6 ANTIBODIES AND USES THEREOF
KR20220111313A (ko) * 2019-12-06 2022-08-09 아블린쓰 엔.브이. TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
KR20230005268A (ko) * 2020-04-24 2023-01-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-cd19 항체 및 이의 용도
KR102705172B1 (ko) * 2020-12-09 2024-09-11 에이치케이이노엔 주식회사 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
CN117440967A (zh) * 2020-12-09 2024-01-23 怡诺安有限公司 抗OX40L抗体、抗OX40L/抗TNFα双特异性抗体及其用途
WO2023017252A1 (en) * 2021-08-10 2023-02-16 Kymab Limited Treatment of atopic dermatitis
AU2024322975A1 (en) * 2023-08-04 2026-03-05 Fortvita Biologics Inc. Anti-ox40l antibody and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978287A1 (en) * 1997-09-25 2000-02-09 Mitsui Chemicals, Inc. MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT
WO2007133290A2 (en) * 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
US7501496B1 (en) * 2004-09-17 2009-03-10 Roche Palo Alto Llc Anti-OX40L antibodies
WO2011073180A1 (en) * 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
US8551477B1 (en) * 2002-09-11 2013-10-08 La Jolla Institute For Allergy And Immunology Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2012015696A1 (en) 2010-07-26 2012-02-02 Baylor Research Institute Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978287A1 (en) * 1997-09-25 2000-02-09 Mitsui Chemicals, Inc. MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT
US8551477B1 (en) * 2002-09-11 2013-10-08 La Jolla Institute For Allergy And Immunology Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same
US7501496B1 (en) * 2004-09-17 2009-03-10 Roche Palo Alto Llc Anti-OX40L antibodies
WO2007133290A2 (en) * 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
WO2011073180A1 (en) * 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use

Also Published As

Publication number Publication date
US10570208B2 (en) 2020-02-25
CN107074951B (zh) 2021-08-03
WO2016022468A1 (en) 2016-02-11
IL250428A0 (en) 2017-03-30
AU2015301338B2 (en) 2021-03-25
US20170349661A1 (en) 2017-12-07
CN107074951A (zh) 2017-08-18
US10167339B2 (en) 2019-01-01
US20190092869A1 (en) 2019-03-28
JP2017523984A (ja) 2017-08-24
EP3194445A4 (en) 2018-05-23
JP6628787B2 (ja) 2020-01-15
EP3194445A1 (en) 2017-07-26
CA2957314A1 (en) 2016-02-11
AU2015301338A1 (en) 2017-02-23
IL250428B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
AU2015301338C1 (en) Antagonistic anti-OX40L antibodies and methods of their use
US20230372400A1 (en) Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US20200216560A1 (en) Anti-MCAM Antibodies And Associated Methods Of Use
CA2861793C (en) Method of providing monoclonal auto-antibodies with desired specificity
US20200165336A1 (en) Mcam antagonists and methods of treatment
US10875916B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F
CA3185180A1 (en) Methods and compositions for treating autoimmune and inflammatory conditions
CN111954680A (zh) IL2Rβ/共同γ链抗体
CA3172120A1 (en) Chimeric antigen receptor specific for human cd45rc and uses thereof
CA2957314C (en) Antagonistic anti-ox40l antibodies and methods of their use
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
HK1212256B (en) Anti-mcam antibodies and associated methods of use

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 APR 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 01 APR 2021

FGA Letters patent sealed or granted (standard patent)